PRMA Consulting is an independent, specialist consultancy solving some of the most challenging market access issues facing pharmaceutical and biotechnology companies today.
Insights
Our services
We excel in understanding the interdependency between pricing, reimbursement, and Health technology assessments...
We assess the current and potential future treatment, pricing, and reimbursement landscape in a target therapy area...
We have developed and maintain strong working relationships with more than 500 payers and KOLs...
We develop and test robust, evidence-based value propositions and messages using methods we have developed based on payer requirements...
Our GVDs are evidence-based and focused on your product’s key value messages. The evidence is mapped to HTA requirements in major markets...
We offer a wide variety of evidence generation projects to support your product; eligible patient population studies, utility studies...
We conduct quantitative research to harness the power of clinician and payer experience to delve deeper into clinical decision-making...
We can help you develop pricing strategies that reflect the true value of your asset. Our insight helps evidence generation, and potential pricing opportunities...
Previous webinars
EUnetHTA Joint Clinical Assessments: where have we come from and where are we going?
Future proofing for the 2020s market access trends
Managed entry agreements lessons from EU5
CAR-T therapy the future begins to take shape
Indication specific pricing the obvious solution
Payer perspectives on cell and gene therapies: opportunities and challenges
Market access considerations for CAR-Ts: insights from ASH
Patient-centricity: shaping value generation for HTA and market access
Market access update key learnings from ASCO and EHA 2017
Market access for PD-1 inhibitors: where are we now?
Hemato-oncology market access update: key learnings from ASH
Keeping ahead of the curve: using HTA learnings to drive market access strategy
The new CDF: opportunities and challenges
>
Market access update: key learnings from EHA and ASCO
PRMA HealthCheck™: benchmarking your evidence against payer requirements
Does 1+1 always equal 2? Valuing combinations
Clarity or confusion: the role of value frameworks in oncology
Health technology assessment and market access learnings from the experience of PD-1 inhibitors
Unlocking the market access potential of immuno-oncology agents
Emerging trends in oncology market access: issues that should be on your radar
Subgroups and market access: developing informed strategy
Thinking strategically about subgroups and ITC
Launching on Phase 2 single-arm data? Real-world evidence strategies to support HTA
Meet the team
Follow us